Abrogation of HLA surface expression using CRISPR/Cas9 genome editing: a step toward universal T cell therapy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • Subject Terms:
      Clustered Regularly Interspaced Short Palindromic Repeats* ; Gene Editing*; Cell- and Tissue-Based Therapy/*methods ; HLA Antigens/*genetics ; T-Lymphocytes/*metabolism; CRISPR-Cas Systems ; Humans
    • Abstract:
      As recent advancements in the chimeric antigen receptor-T cells have revolutionized the way blood cancers are handled, potential benefits from producing off-the-shelf, standardized immune cells entail the need for development of allogeneic immune cell therapy. However, host rejection driven by HLA disparity in adoptively transferred allogeneic T cells remains a key obstacle to the universal donor T cell therapy. To evade donor HLA-mediated immune rejection, we attempted to eliminate T cell's HLA through the CRISPR/Cas9 gene editing system. First, we screened 60 gRNAs targeting B2M and multiple sets of gRNA each targeting α chains of HLA-II (DPA, DQA and DRA, respectively) using web-based design tools, and identified specific gRNA sequences highly efficient for target deletion without carrying off-target effects. Multiplex genome editing of primary human T cells achieved by the newly discovered gRNAs yielded HLA-I- or HLA-I/II-deficient T cells that were phenotypically unaltered and functionally intact. The overnight mixed lymphocyte reactions demonstrated the HLA-I-negative cells induced decreased production of IFN-γ and TNF-α in alloreactive T cells, and deficiency of HLA-I/II in T cells further dampened the inflammatory responses. Taken together, our approach will provide an efficacious pathway toward the universal donor cell generation by manipulating HLA expression in therapeutic T cells.
    • References:
      Immunology. 2007 Dec;122(4):476-85. (PMID: 17645498)
      Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2862-70. (PMID: 19182257)
      Blood. 2018 Aug 23;132(8):804-814. (PMID: 29895668)
      Sci Transl Med. 2017 Jan 25;9(374):. (PMID: 28123068)
      Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6313-8. (PMID: 9177214)
      N Engl J Med. 2019 Jan 3;380(1):45-56. (PMID: 30501490)
      Science. 2016 Jan 1;351(6268):84-8. (PMID: 26628643)
      Nat Methods. 2014 Feb;11(2):122-3. (PMID: 24481216)
      Nat Med. 2018 Oct;24(10):1499-1503. (PMID: 30275568)
      N Engl J Med. 2018 Feb 1;378(5):439-448. (PMID: 29385370)
      Nature. 2016 Jan 28;529(7587):490-5. (PMID: 26735016)
      J Exp Med. 1979 Aug 1;150(2):246-55. (PMID: 88499)
      Proc Natl Acad Sci U S A. 1997 May 13;94(10):5249-54. (PMID: 9144223)
      Nucleic Acids Res. 2015 Jan;43(Database issue):D423-31. (PMID: 25414341)
      Stem Cell Reports. 2016 Oct 11;7(4):619-634. (PMID: 27641646)
      Ophthalmology. 2018 Nov;125(11):1765-1775. (PMID: 29884405)
      J Am Heart Assoc. 2018 Dec 4;7(23):e010239. (PMID: 30488760)
      PLoS One. 2019 May 9;14(5):e0216815. (PMID: 31071196)
      Nature. 2017 Mar 2;543(7643):113-117. (PMID: 28225754)
      Eur J Ophthalmol. 1999 Jul-Sep;9(3):217-30. (PMID: 10544978)
      Cancer Res. 2015 Sep 15;75(18):3853-64. (PMID: 26183927)
      Hum Immunol. 2004 Apr;65(4):282-90. (PMID: 15120183)
      Blood. 2014 Jun 19;123(25):3855-63. (PMID: 24719405)
      Nature. 2018 Jun;558(7709):307-312. (PMID: 29849141)
      J Clin Invest. 2014 Apr;124(4):1810-20. (PMID: 24569453)
      Tumour Biol. 2008;29(1):28-34. (PMID: 18497546)
      Nat Rev Immunol. 2007 May;7(5):340-52. (PMID: 17438575)
      J Biol Chem. 2004 Oct 1;279(40):41319-32. (PMID: 15247294)
      J Immunol. 2001 Mar 1;166(5):2917-21. (PMID: 11207239)
      Nat Biotechnol. 2019 Mar;37(3):252-258. (PMID: 30778232)
      Nucleic Acids Res. 2016 Jul 8;44(W1):W272-6. (PMID: 27185894)
      Bioinformatics. 2015 Nov 15;31(22):3676-8. (PMID: 26209430)
      Nat Med. 2018 May;24(5):563-571. (PMID: 29713085)
      Clin Exp Immunol. 1996 May;104(2):366-73. (PMID: 8625534)
      Circ Res. 2015 Jul 3;117(2):121-8. (PMID: 25940550)
      Nat Rev Immunol. 2019 Feb;19(2):73-74. (PMID: 30631206)
      Clin Cancer Res. 2017 May 1;23(9):2255-2266. (PMID: 27815355)
      Blood. 2013 Aug 22;122(8):1341-9. (PMID: 23741009)
      Blood. 2005 Apr 15;105(8):3051-7. (PMID: 15632206)
      Blood. 2012 Jun 14;119(24):5697-705. (PMID: 22535661)
      Blood Cancer J. 2019 Jan 22;9(2):10. (PMID: 30670684)
      Nucleic Acids Res. 2007;35(2):595-605. (PMID: 17175541)
      J Immunol. 2019 Mar 15;202(6):1895-1903. (PMID: 30700588)
      Cell Stem Cell. 2019 Apr 4;24(4):566-578.e7. (PMID: 30853558)
      N Engl J Med. 2017 Dec 28;377(26):2531-2544. (PMID: 29226797)
      Nat Methods. 2015 Mar;12(3):237-43, 1 p following 243. (PMID: 25664545)
      Lancet. 2015 Feb 7;385(9967):509-16. (PMID: 25458728)
      Nucleic Acids Res. 2015 Mar 31;43(6):3128-42. (PMID: 25753668)
      PLoS One. 2015 Apr 24;10(4):e0124633. (PMID: 25909470)
      Nat Biotechnol. 2017 Aug;35(8):765-772. (PMID: 28504668)
      Science. 2020 Feb 28;367(6481):. (PMID: 32029687)
    • Accession Number:
      0 (HLA Antigens)
    • Publication Date:
      Date Created: 20201021 Date Completed: 20210125 Latest Revision: 20210125
    • Publication Date:
      20231215
    • Accession Number:
      PMC7576162
    • Accession Number:
      10.1038/s41598-020-74772-9
    • Accession Number:
      33082438